Nicholasville, KENTUCKY1 Active Studies

Multiple Sclerosis Clinical Trials in Nicholasville, KENTUCKY

Find 1 actively recruiting multiple sclerosis clinical trials in Nicholasville, KENTUCKY. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
1,050
Enrolling

Recruiting Multiple Sclerosis Studies in Nicholasville

About Multiple Sclerosis Clinical Trials in Nicholasville

Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the protective covering of nerve fibers, causing communication problems between the brain and body. Symptoms vary widely and can include vision problems, fatigue, and mobility issues. Disease-modifying therapies have significantly improved outcomes.

There are currently 1 multiple sclerosis clinical trials recruiting participants in Nicholasville, KENTUCKY. These studies are seeking a combined 1,050 participants. Research is being sponsored by Immunic AG. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Sclerosis Clinical Trials in Nicholasville — FAQ

Are there multiple sclerosis clinical trials in Nicholasville?

Yes, there are 1 multiple sclerosis clinical trials currently recruiting in Nicholasville, KENTUCKY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Nicholasville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Nicholasville research site will contact you about next steps.

Are clinical trials in Nicholasville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Nicholasville studies also compensate for your time and travel.

What multiple sclerosis treatments are being tested?

The 1 active trials in Nicholasville are testing new therapies including novel drugs, biologics, and treatment approaches for multiple sclerosis.

Data updated March 2, 2026 from ClinicalTrials.gov